An older breast cancer drug helped one woman after newer drugs stopped working
Original title: Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies: case report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
The drug is already used for this cancer, but this result comes from just one patient.
The short version
One woman with breast cancer that spread to her brain got better on an older drug, and it kept helping for more than two years.
What was studied. This is a report about one patient. She was a 37-year-old woman with HER2 positive breast cancer that had spread to her brain and was causing symptoms. Her cancer got worse after two newer HER2 drugs, T-DXd and tucatinib.
What they found. Her doctors then gave her an older HER2 drug called T-DM1. It was her fourth treatment. The cancer in her brain responded, and that response lasted over 24 months. She tolerated the drug well, and her side effects could be managed.
What this means, and what it doesn't
What it could mean: T-DM1 may still help some people even after newer HER2 drugs stop working. It is already an available treatment, and it is easy to give. If newer drugs stop working for you, or you cannot take them, you could ask your doctor whether T-DM1 is an option.
What it doesn't mean: This is one person's story, not a trial. It does not show that T-DM1 will work this way for other people. Doctors still do not know the best order to give these drugs. The authors say more studies are needed. This is not a promise of a cure.
Source: PubMed, July 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.